Biotechnology firm Transgenomic, along with four global biopharmaceutical firms, is starting a new pilot clinical study with its Multiplexed ICE COLD-PCR (MX-ICP) liquid biopsy technology.
The firm developed Multiplexed ICE COLD-PCR for the ultra-sensitive detection of very-low-level genetic alterations, allowing it to be used as a tool for the identification of cancer biomarkers.
The technology reportedly works with virtually any type of patient sample, including tissue, blood, plasma, and urine.
The study has been designed to validate the accuracy and utility of using MX-ICP-based liquid biopsies, which analyse circulating tumour DNA in the blood to guide and monitor cancer clinical trials.
Transgenomic president and CEO Paul Kinnon said: "One of the most important attributes of our MX-ICP technology is its potential for enabling the routine use of DNA analyses to guide and monitor cancer treatment, by replacing invasive and costly tissue biopsies with easily-accessible blood tests.
"A similar pilot study partnered with another major oncology company that we started earlier this year is going very well, fuelling our optimism that these studies will confirm the broad potential of MX-ICP liquid biopsies in diagnosing, monitoring, and managing cancer."
The company will include variety of cancers and several different sequencing platforms in the study.
In the study, Transgenomi will have access to patient blood samples from the participating firms' relevant clinical trials.
It will help the firm to generate supporting data to demonstrate the correlation between genomic analyses from FFPE tissue samples and those obtained using plasma samples enriched with Multiplexed ICE COLD-PCR.